Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea.
Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
J Korean Med Sci. 2021 Dec 13;36(48):e336. doi: 10.3346/jkms.2021.36.e336.
In 2020, the novel coronavirus disease 2019 (COVID-19) began to spread worldwide and remains an ongoing medical challenge. This case series reports on the clinical features and characteristics of patients with inflammatory bowel disease (IBD) and confirmed COVID-19 infection. From February 2020 to March 2021, nine patients with IBD had confirmed COVID-19 across four hospitals in Korea. The median age at COVID-19 diagnosis was 42 years. Six patients were male, and seven patients had ulcerative colitis (UC). No patients required oxygen therapy, intensive care unit hospitalizations, or died. The most common symptom was fever, and gastrointestinal (GI) symptoms developed as diarrhea in five patients with UC. Oral steroids were used to combat UC aggravation in two patients. In this case series of nine IBD patients diagnosed with COVID-19 in Korea, the clinical presentation was predominately a mild respiratory tract infection. Most patients with UC developed new GI symptoms including diarrhea.
2020 年,新型冠状病毒病 2019(COVID-19)开始在全球范围内传播,仍然是一个持续存在的医学挑战。本病例系列报告了炎症性肠病(IBD)和确诊 COVID-19 感染患者的临床特征和特点。从 2020 年 2 月至 2021 年 3 月,韩国的四家医院共收治了 9 例确诊 COVID-19 的 IBD 患者。COVID-19 诊断时的中位年龄为 42 岁。6 名患者为男性,7 名患者患有溃疡性结肠炎(UC)。没有患者需要氧疗、入住重症监护病房或死亡。最常见的症状是发热,5 例 UC 患者出现腹泻等胃肠道(GI)症状。有 2 例患者使用口服类固醇治疗 UC 加重。在这项韩国 9 例确诊 COVID-19 的 IBD 患者的病例系列研究中,临床表现主要为轻度呼吸道感染。大多数 UC 患者出现包括腹泻在内的新的胃肠道症状。